Using ultrasound in preoperative mapping and surveillance of arteriovenous grafts for haemodialysis improves patency rates: Single-centre experience

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F25%3A10159595" target="_blank" >RIV/00098892:_____/25:10159595 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/25:10489398 RIV/61989592:15110/25:73636515 RIV/00064165:_____/25:10489398

Výsledek na webu

<a href="https://journals.sagepub.com/doi/10.1177/11297298241308377?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed" target="_blank" >https://journals.sagepub.com/doi/10.1177/11297298241308377?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1177/11297298241308377" target="_blank" >10.1177/11297298241308377</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Using ultrasound in preoperative mapping and surveillance of arteriovenous grafts for haemodialysis improves patency rates: Single-centre experience

Popis výsledku v původním jazyce

Background: This study aimed to evaluate patency outcomes of arteriovenous grafts (AVGs) before and after using Duplex doppler ultrasonography (DUS) in preoperative mapping and surveillance of AVG. Methods: In this single-centre, retrospective cohort study 212 patients receiving AVGs from January 2009 to December 2022 were included. In group 1, the creation of AVG as well as screening was based on physical examination alone. In contrast, DUS was used in the preoperative mapping and surveillance of AVG in group 2. The patients also received sulodexide as supplemental medication. Outcomes included primary and secondary patency. The Mann-Whitney U-test was used to compare the differences between groups in number of thrombectomies and preemptive percutaneous transluminal angioplasties (PTAs). Results: Group 1 included 90 AVGs. The mean follow-up time was 333 days (range: 1–1230 days, standard deviation: 318 days). The primary and secondary graft patency rates were 13.3%, 62.2% at 6 months; 2.2%, 52.1% at 12 months; 0%, 44.3% at 24 months and 0%, 44.3% at 36 months respectively. During the 7-year surveillance of AVG, significantly more thrombectomies were performed than preemptive PTA (p &lt; 0.0001). Group 2 included 122 AVGs. The mean follow-up time was 584 days (range: 1–2040 days, standard deviation: 463 days). The primary and secondary graft patency rates were 54.9%, 95.9% at 6 months; 29.5%, 77.8% at 12 months; and 9.8%, 56.5% at 24 months; 2.5%, 47.1% at 36 months respectively. The primary and secondary graft patency was significantly longer (p &lt; 0.0001, p = 0.002). During the 7-year surveillance of AVG there were significantly more preemptive PTAs performed (p = 0.0004). Conclusions: The primary and secondary patency of AVG were significantly improved after using DUS in preoperative mapping and surveillance. DUS surveillance led to a decrease in AVG occlusion. A potential positive effect of sulodexide on patency rate of AVG needs more research.

Název v anglickém jazyce

Using ultrasound in preoperative mapping and surveillance of arteriovenous grafts for haemodialysis improves patency rates: Single-centre experience

Popis výsledku anglicky

Background: This study aimed to evaluate patency outcomes of arteriovenous grafts (AVGs) before and after using Duplex doppler ultrasonography (DUS) in preoperative mapping and surveillance of AVG. Methods: In this single-centre, retrospective cohort study 212 patients receiving AVGs from January 2009 to December 2022 were included. In group 1, the creation of AVG as well as screening was based on physical examination alone. In contrast, DUS was used in the preoperative mapping and surveillance of AVG in group 2. The patients also received sulodexide as supplemental medication. Outcomes included primary and secondary patency. The Mann-Whitney U-test was used to compare the differences between groups in number of thrombectomies and preemptive percutaneous transluminal angioplasties (PTAs). Results: Group 1 included 90 AVGs. The mean follow-up time was 333 days (range: 1–1230 days, standard deviation: 318 days). The primary and secondary graft patency rates were 13.3%, 62.2% at 6 months; 2.2%, 52.1% at 12 months; 0%, 44.3% at 24 months and 0%, 44.3% at 36 months respectively. During the 7-year surveillance of AVG, significantly more thrombectomies were performed than preemptive PTA (p &lt; 0.0001). Group 2 included 122 AVGs. The mean follow-up time was 584 days (range: 1–2040 days, standard deviation: 463 days). The primary and secondary graft patency rates were 54.9%, 95.9% at 6 months; 29.5%, 77.8% at 12 months; and 9.8%, 56.5% at 24 months; 2.5%, 47.1% at 36 months respectively. The primary and secondary graft patency was significantly longer (p &lt; 0.0001, p = 0.002). During the 7-year surveillance of AVG there were significantly more preemptive PTAs performed (p = 0.0004). Conclusions: The primary and secondary patency of AVG were significantly improved after using DUS in preoperative mapping and surveillance. DUS surveillance led to a decrease in AVG occlusion. A potential positive effect of sulodexide on patency rate of AVG needs more research.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

The Journal of Vascular Access

ISSN

1129-7298

e-ISSN

1724-6032

Svazek periodika

26

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

1871-1877

Kód UT WoS článku

001385576900001

EID výsledku v databázi Scopus

2-s2.0-85213537678